Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Clinical trial NCT03478462 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03478462
Sponsor: Cellectar Biosciences, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Pediatric Solid Tumor Pediatric Lymphoma Pediatric Brain Tumor DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcoma Osteosarcoma

Start date: 2019-04-30
Primary completion: 2026-08-25
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.